Nkarta 3Q 2026: EPS ($0.45) — 10-Q Summary
Nkarta reported a wider net loss in 3Q 2026 as research and development spending rose, primarily reflecting higher clinical spending and manufacturing and materials expenses for NKX019. Lower interest income and other income also contributed to the year-over-year increase in the loss.Financial High…
Story updates
09:44:48 PM UTC
SquawkNews
Nkarta reported a third-quarter 2026 net loss of $33.3 million, or $0.45 per basic and diluted share, compared with a $21.7 million loss in the year-ago quarter. Research and development expenses rose to $29.5 million, while cash, cash equivalents, restricted cash and investments totaled $216.0 mil…